title: Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.
abstract: Palivizumab (Synagis; Abbott Laboratories), a humanized, monoclonal antibody, prevents lower respiratory tract infection by respiratory syncytial virus (RSV). RSV causes significant morbidity and mortality in young children worldwide and is particularly severe in pre-term infants, children with cardiopulmonary disease, and the immunosuppressed population. The first such genetically engineered agent to be used effectively against a human infectious disease, palivizumab significantly reduces the number of hospitalizations caused by RSV in high-risk infants. This article reviews the preclinical development and clinical experience of palivizumab.
authors.affiliation: Global Research and Development, Abbott Laboratories, Abbott Park, IL, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Pollack
authors.forename: Jessie R
authors.initials: JR
authors.lastname: Groothuis
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D000069455:Palivizumab; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab